CDSCO Guidelines for Biological Clinical Trials in India

CDSCO Guidelines for Biological Clinical Trials in India (NDCT Rules 2019) define a structured regulatory pathway for evaluating biologics through phased human studies. The framework ensures safety, quality, and efficacy through strict documentation, ethical approval, GCP compliance, and scientific review. It supports safe development of vaccines, gene therapies, and other biologics before market authorization in India under biologics regulation India.

What are Biological Clinical Trials?

Biological clinical trials are human studies conducted to evaluate biologic products before they are approved for use. Medical products obtained from living sources like human cells, animals, or microorganisms are known as biologicals. They may be used to prevent diseases, diagnose medical conditions, or treat illnesses.

Examples of biologic products include:

Gene therapies
Vaccines
Cellular therapies
Human cells and tissues used for transplantation such as ligaments, bone, and tendons
Blood and blood components used for transfusion or further processing
Diagnostic tests used to detect infectious agents like HIV in blood screening
Allergenic products used for diagnosis and treatment, such as allergy injections

These biologics are then evaluated through phased clinical trials. Early studies focus on immune response and safety by assessing antibodies, cytokines, T-cell activity, and possible immune-related reactions. Later studies assess effectiveness in preventing or treating disease and help determine the appropriate dose. Large multicentric studies then confirm safety and efficacy across different populations before approval.

Regulatory Framework in India

The Biologics regulation India framework is governed under the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945, along with rules for genetically engineered organisms notified under the Environment (Protection) Act, 1986 and the Rules, 1989.

The regulatory system is supported by multiple committees and guidance frameworks that oversee biosafety and biological development, including:

Guidelines for Recombinant DNA Safety (1990)
CDSCO industry guidance documents
Institutional Biosafety Committee (IBSC)
Review Committee on Genetic Manipulation (RCGM)
Genetic Engineering Appraisal Committee (GEAC)

For clinical trials specifically, Biological studies must follow the New Drugs and Clinical Trials (NDCT) Rules, 2019. The sponsor needs to submit the application using Form CT-04. They must follow Good Clinical Practice (GCP) guidelines and set up proper quality assurance systems. All safety information, including serious adverse events, should be reported within the required time limits.

Biological products are evaluated in specialised facilities such as the Central Drug Laboratory, Kasauli and the National Institute of Biologicals, Noida, which handle quality testing and batch release of products including vaccines, blood components, diagnostic reagents, and other biologics.

Biological Approval Process in India

Biological products undergo multiple levels of evaluation before approval:

Institutional Scientific Committee review
Institutional and National Ethics Committee approval
Import permission and regulatory approval by DCGI under the Ministry of Health and Family Welfare
Genetic engineering appraisal under environmental authorities

These steps ensure safety, scientific validation, and ethical compliance before clinical use.

Clinical Trial Phases for Biologicals

The clinical trials are conducted in structured phases under the NDCT Rules 2019 Biologicals as explained below:

Phase I (Human/Clinical Pharmacology): Focuses on safety and immunogenic response, including antibody levels, cytokines, and T-cell responses.
Phase II (Exploratory Trials): Evaluates therapeutic or preventive efficacy, dose determination, and immune response monitoring in targeted populations.
Phase III (Confirmatory Trials): Large multicentric studies confirm safety and efficacy, including evaluation across diverse populations and monitoring of immunological parameters.

Clinical Trial Phases of Biologicals

Figure1

Clinical Trial Application and Documentation Requirements

To initiate a trial under CDSCO biologics guidelines, sponsors must submit an application in Form CT-04 through the SUGAM portal. The submission must include comprehensive regulatory and scientific documentation to support evaluation of safety, quality, and trial design.

A Biological Clinical Trial application in India must be supported by detailed documentation of the following requirements:

Application is submitted in Form CT-04 via SUGAM portal
Must include chemistry, manufacturing, and control (CMC) data
Preclinical study results must be provided
Clinical trial protocol and investigator details are required
Regulatory status in other countries must be included
Information on product composition, manufacturing process, stability, and quality control systems is mandatory
Ethical approval need to be obtained from the Institutional Ethics Committees
Sponsors must maintain Standard Operating Procedures (SOPs)
Compliance with Good Clinical Practice (GCP) and regulatory requirements must be ensured throughout the trial lifecycle

Preclinical and Post-market Requirements for Biological Products

Clinical trial applications for Biological products require compliance with CDSCO norms and the prescribed industry guidance. For marketing authorization, the applicant must submit the application and supporting documents as per regulatory requirements. Manufacturing for commercial purposes is reviewed under separate processes compared to manufacturing of Phase III clinical trial batches.

Pre-clinical study requirements include:

Drug-related information such as identification, pharmacokinetics, adverse effects, and usage profile
Details of route of administration and absorption characteristics
Elimination profile and mode of action of the Drug
Pharmacodynamic studies to evaluate biochemical and physiological effects
Toxicology studies to assess onset, severity, and duration of toxic effects

After completion of pre-clinical evaluation, the Review Committee on Genetic Manipulation (RCGM) provides guidance for proceeding to clinical trials under CDSCO regulatory framework.

Post-market requirements for biologics include:

A pharmacovigilance system to detect, assess, monitor, and prevent adverse effects after product use
Reporting and analysis of adverse reactions occurring after administration of the product.
Post-marketing studies (PMS) to continuously monitor the safety of the product after-market release

Short Summary

Biological clinical trials in India are conducted under CDSCO biologics guidelines to evaluate the safety, efficacy, and quality of biologic products such as vaccines, gene therapies, and cellular treatments before they are approved for public use.
The CDSCO guidelines under the NDCT Rules 2019 provide a strict regulatory framework that governs every stage of clinical development, from application submission to final approval.
These trials require comprehensive documentation, including chemistry, manufacturing and control (CMC) data, preclinical study results, and approval from Institutional Ethics Committees to ensure scientific and ethical compliance.
Clinical evaluation is carried out in phased studies where early phases focus on safety and immune response, while later phases assess effectiveness, dosing, and large-scale population outcomes.

Conclusion

The CDSCO Biologics guidelines are carefully regulated under the CDSCO guidelines and NDCT Rules 2019 to ensure safety, quality, and scientific reliability. They require strict documentation, phased testing, and regulatory approvals before approval. With compliance to GCP and ethical standards, biologics are carefully evaluated for safety and efficacy. This framework supports reliable clinical research while protecting patient safety and maintaining strong regulatory oversight.

References

Central Drugs Standard Control Organization. biologicals. Accessed May 8, 2026. https://cdsco.gov.in/opencms/opencms/en/biologicals/
Genetic Engineering Appraisal Committee (GEAC). Guidelines For Generating Pre-Clinical And Clinical Data For Rdna Vaccines, Diagnostics And Other Biologicals, 1999. Accessed May 8, 2026. http://www.geacindia.gov.in/resource-documents/biosafety-regulations/guidelines-and-protocols/Guidelines-for-generating-preclinical-and-clinical-data-1999.pdf
Lokesh C, Sonia K, Kamaraj R. Regulatory Requirements for Biological product approval process in India. Rese Jour of Pharm and Technol. 2020;13(2):1050. doi:10.5958/0974-360X.2020.00193.6
CDSCO. Guidance For Industry (Biologicals). Accessed May 8, 2026. https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/biologicals/Guidance-for-IndusrtBiologicals.pdf